Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

FDA grants accelerated approval to selinexor for multiple myeloma

On July 3, 2019, the Food and Drug Administration granted accelerated approval to selinexor in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Efficacy was evaluated in 122 patients enrolled in Part 2 of STORM (KCP-330-012; NCT02336815), a multicentre, single-arm, open-label study of patients with RRMM who had previously received three or more anti-myeloma treatment regimens including an alkylating agent, glucocorticoids, bortezomib, carfilzomib, lenalidomide, pomalidomide, and an anti-CD38 monoclonal antibody.

In addition, the disease was refractory to glucocorticoids, a proteasome inhibitor, an immunomodulatory agent, an anti-CD38 monoclonal antibody, and to the last line of therapy.

These patients were treated with selinexor (80 mg) in combination with dexamethasone (20 mg) on days 1 and 3 of every week.

The approval was based on efficacy and safety in a prespecified subgroup analysis of 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab.

The overall response rate was 25.3% (95% CI: 16.4, 36), with 1 stringent complete responses (CR), no CR, 4 very good partial responses and 16 partial responses.

The median time to first response was 4 weeks (range: 1 to 10 weeks).

The median response duration was 3.8 months (95% CI: 2.3, not estimable).

The efficacy evaluation was supported by additional information from an ongoing, randomised trial in patients with multiple myeloma.

Common adverse reactions reported in at least 20% of patients include thrombocytopenia, fatigue, nausea, anaemia, decreased appetite, decreased weight, diarrhoea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.

The recommended selinexor dose is 80 mg in combination with dexamethasone taken orally on days 1 and 3 of each week.

Source: FDA

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation